1. Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients
   Daniel L Hertz et al, 2017, Pharmacogenomics CrossRef
2. Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole
   Jacqueline M Dempsey et al, 2019, Pharmacogenomics CrossRef
3. Assay of serum E2 concentration in postmenopausal breast cancer patients using a high-sensitivity RIA method is generally useful
   Masami Morimoto et al, 2016, The Journal of Medical Investigation CrossRef
4. Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients
   Valentina Sini et al, 2017, Pharmacogenomics CrossRef
5. A Polymorphism at the 3'-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma
   Lei Liu et al, 2013, International Journal of Molecular Sciences CrossRef
6. The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors
   Xiaoman Liu et al, 2016, Expert Opinion on Drug Metabolism & Toxicology CrossRef
7. In silico analysis and experimental validation shows negative correlation between miR-1183 and cell cycle progression gene 1 expression in colorectal cancer
   Syeda Alina Fatima et al, 2023, PLOS ONE CrossRef
8. miRNA clusters as therapeutic targets for hormone-resistant breast cancer
   Gianpiero Di Leva et al, 2015, Expert Review of Endocrinology & Metabolism CrossRef
9. Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis
   Osvaldo Artigalás et al, 2015, BMC Medicine CrossRef
10. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial
    Duveken B. Y. Fontein et al, 2014, Breast Cancer Research and Treatment CrossRef
11. The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients
    Murtala B. Abubakar et al, 2014, Pharmacogenetics and Genomics CrossRef
12. MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers
    Tushar Singh Barwal et al, 2021, International Journal of Molecular Sciences CrossRef
13. Aromatase Inhibitors Beyond Breast Cancer: Endometrium Versus Breast Puzzle and Other Issues
    Lev M. Berstein, 2015, Resistance to Aromatase Inhibitors in Breast Cancer CrossRef